In an APP/PS1/tau mouse model of Alzheimer’s disease, lixisenatide reduced tau neurofibrillary tangles, amyloid-β plaques and neuroinflammation, as indicated by decreased microglial activation in the hippocampus [96]. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.